<DOC>
	<DOCNO>NCT00109512</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double-blind , placebo-controlled , parallel-group study subject randomize one three treatment group , placebo , 75 mg 150 mg 1:1:1 ratio . Study drug administer daily 12 week . After last dose end Week 12 , follow-up continue every 4 week 12 week .</brief_summary>
	<brief_title>Endometriosis Trial : Study NBI-56418 Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Inclusion Criteria Be female , age 18 49 year , inclusive . Have pelvic pain dysmenorrhea result Composite Pelvic Sign Symptoms Score ( CPSSS ) ≥ 6 . Have diagnosis endometriosis make follow laparoscopic visualization disease within last 5 year start screen . Have regular menstrual cycle ( 28 day ±5 day ) great equal 2 year . For cycle immediately precedes dose , cycle length determine part medical history . Have Body Mass Index 18 30 kg/m2 . Agree use two form nonhormonal contraception ( unless sterilize tubal ligation ) great equal 3 month prior Screening ovulation return menses treatment . Have negative serum pregnancy test Screening negative urine pregnancy test prior dose begin Week 1 . Have cervical smear negative malignancy Screening . Be willing comply study procedure restriction . Be able read , understand , sign ICF ( informed consent form ) enter study . Be willing provide authorization access personal health information conjunction US Health Insurance Portability Accountability Act ( HIPAA ) . Exclusion Criteria Are currently receive GnRH agonist GnRH antagonist , receive agent within 6 month Screening . Have nonresponsive GnRH agonist antagonist therapy management endometriosis . Are currently receive hormonal therapy include oral contraceptive pill receive agent within 3 month Screening . Are concurrent medical treatment/medications surgical hormonal treatment oral contraceptive endometriosis within 3 month Screening . Have uterine fibroid pelvic lesion great equal 3 cm diameter verify ultrasound . Are currently breastfeed infant . Are use steroid preparation , take route ( e.g. , oral , inhale ) chronic regular basis within 3 month Screening . Have unstable medical condition chronic disease ( include history neurological [ include cognitive ] , hepatic , renal , cardiovascular , gastrointestinal , pulmonary , endocrine disease ) , malignancy could confound interpretation study outcomes . Have chronic pelvic pain cause endometriosis . Have psychological disorder accord criterion indicate Diagnostics Statistical Manual Mental Disorders , 4th edition within one year screen . Such disorder include , limited , alcohol substance abuse/dependence . Have history poor compliance clinical research study . Have medically significant illness 30 day begin Week 1 . Have medically significant abnormality observe upon Screening begin Week 1 physical examination , baseline measurement . Findings outside standard reference range jointly approve NBI 's ( Neurocrine Biosciences ) Medical Monitor consider eligible study . Are use investigational drug within 2 month Screening . Have positive human immunodeficiency virus antibody ( HIV Ab ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) assay Screening history positive result . Have allergy , hypersensitivity , intolerance GnRH agonist antagonist .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>endometriosis</keyword>
	<keyword>pelvic pain</keyword>
	<keyword>painful period</keyword>
	<keyword>dysmenorrhea</keyword>
	<keyword>painful menstruation</keyword>
	<keyword>GnRH</keyword>
	<keyword>agonist</keyword>
	<keyword>antagonist</keyword>
	<keyword>menstrual pain</keyword>
</DOC>